Next-Generation Therapeutics for IBD

被引：26

作者：

Löwenberg M. ^{[1
]}

D’Haens G. ^{[1
,2
]}

机构：

[1] Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam

[2] Robarts Clinical Trials, Amsterdam

来源：

Current Gastroenterology Reports | 2015年 / 17卷 / 6期

关键词：

Crohn’s disease (CD); Inflammatory bowel disease (IBD); Integrin inhibitors; Small molecules; Tofacitinib; Ulcerative colitis (UC); Vedolizumab;

D O I：

10.1007/s11894-015-0444-2

中图分类号：

学科分类号：

摘要：

Various novel drugs have recently been evaluated in clinical trials showing promising effects in patients with inflammatory bowel disease (IBD). Here, we summarize the recent literature in the area of emerging therapies in the field of IBD, with specific focus on anti-integrin antibodies, such as vedolizumab (anti-α4β7) and etrolizumab (anti-rhuMAb β7), and the Janus kinase (JAK) inhibitor tofacitinib. Moreover, we will discuss efficacy and safety data of golimumab (a new subcutaneous anti-tumor necrosis factor (TNF) antibody), Avaxia (an orally delivered anti-TNF antibody), and Budesonide MMX; all have been developed for the treatment of ulcerative colitis. Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn’s disease patients. © 2015, The Author(s).

引用

页数：8

共 36 条

[1]

Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Et al., Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial, Gastroenterology, 132, pp. 52-65, (2007)

[2]

Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Et al., Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial, Lancet, 359, pp. 1541-1549, (2002)

[3]

Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Et al., Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, pp. 2462-2476, (2005)

[4]

Sandborn W.J., van Gert A., Reinisch W., Colombel J.F., D'Haens G., Wolf D.C., Et al., Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 142, pp. 257-265, (2012)

[5]

Sandborn W.J., Feagan B.G., Marano C., Zhang H., Strauss R., Johanns J., Et al., Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, pp. 85-95, (2014)

[6]

Allez M., Karmiris K., Louis E., van Gert A., Ben-Horin S., Klein A., Et al., Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects, J Crohns Colitis, 4, pp. 355-366, (2010)

[7]

D'Haens G.R., Panaccione R., Higgins P.D., Vermeire S., Gassull M., Chowers Y., Et al., The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and how to predict response?, Am J Gastroenterol, 106, pp. 199-212, (2011)

[8]

Ben-Horin S., Chowers Y., Review article: loss of response to anti-TNF treatments in Crohn’s disease, Aliment Pharmacol Ther, 33, pp. 987-995, (2011)

[9]

Billioud V., Sandborn W.J., Peyrin-Biroulet L., Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review, Am J Gastroenterol, 106, pp. 674-684, (2011)

[10]

Gisbert J.P., Panes J., Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review, Am J Gastroenterol, 104, pp. 760-767, (2009)

← 1 2 3 4 →